— Know what they know.
Not Investment Advice

ORGS OTC

Orgenesis Inc.
1W: +16.0% 1M: +65.7% 3M: +45.0% YTD: +286.7% 1Y: -26.6% 3Y: -90.7% 5Y: -98.8%
$0.58
+0.03 (+5.45%)
 
Weekly Expected Move ±739.3%
$-8 $-4 $1 $5 $9
OTC · Healthcare · Biotechnology · Tech Score Buy · Power 67 · $5.7M mcap · 7M float · 0.0071% daily turnover · Short 76% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$5.7M
52W Range0.001-1
Volume357
Avg Volume518
Beta3.14
Dividend—
Analyst Ratings
1 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOVered Caplan
Employees77
SectorHealthcare
IndustryBiotechnology
IPO Date2012-03-13
20271 Goldenrod Lane
Germantown, MD 20876
US
480 659 6404
About Orgenesis Inc.

Orgenesis Inc. is a global biotechnology firm dedicated to the field of cell and gene therapies. The company has engineered an innovative Point of Care (POCare) platform. This system incorporates a portfolio of licensed POCare therapeutics, which are manufactured and prepared using automated, self-contained POCare technology within a cooperative network. Orgenesis primarily concentrates on autologous therapies, developing customized processes and systems for each treatment. These utilize a closed, automated processing methodology, validated for safe and compliant production directly at the patient's location, facilitating immediate therapeutic application. Established in 2008 as Business Outsourcing Service, Inc., the company adopted the name Orgenesis Inc. in August 2011 and is headquartered in Germantown, Maryland.

Recent Insider Trades

NameTypeSharesPriceDate
MALIK ARIEL 0 — 2025-03-05
Adler Yaron A-Award 1,750 $0.98 2024-12-12
PELAVIN ADAM A-Award 1,250 $0.98 2024-12-12
PELAVIN ADAM A-Award 625 $0.98 2024-12-12
Nanda Ashish A-Award 1,835 $0.98 2024-12-12

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms